Impact of modern minimally invasive approaches on pulmonary resection outcomes: a narrative review Authors: China Stegall, John F Lazar Published: 2026 ABSTRACT AbstractBackground and ObjectiveAnatomic pulmonary resection remains the gold standard for resectable non-small cell lung cancer (NSCLC). This review evaluates the evolution, intraoperative outcomes, clinical efficiency, oncological adequacy, and cost-effectiveness of minimally invasive thoracic surgery (MITS) relative to traditional open thoracotomy.MethodsA systematic literature search was conducted in PubMed, Cochrane Library, and Wiley Library for studies published through early 2026, prioritizing randomized controlled trials (RCTs) and large-scale registry analyses comparing video-assisted thoracoscopic surgery (VATS), robotic-assisted thoracic surgery (RVATS), and open thoracotomy.Key Content and FindingsMITS (comprising VATS and RVATS) is associated with significantly lower perioperative mortality, reduced postoperative pain, shorter hospital stays, and fewer complications compared to open thoracotomy. While intraoperative conversion remains a risk, robotic platforms exhibit lower conversion rates than VATS in several large series. Oncologically, all three modalities provide equivalent nodal upstaging and disease-free survival (DFS), provided oncological principles are rigorously maintained. While robotic surgery incurs higher procedural costs, these are partially mitigated by reduced postoperative resource utilization.ConclusionsMITS has become the standard of care for early-stage NSCLC. Recent data suggest that robotic platforms may offer advantages in technical precision and lower conversion rates, although VATS remains a highly cost-effective and efficacious approach. Future innovations in single-port robotics continue to advance the reduction of surgical trauma.Keywords: Pulmonary resection, surgical outcomes, video-assisted thoracoscopic surgery (VATS), robotic-assisted thoracic surgery (RVATS), minimally invasive surgery Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of cases (1). For patients with resectable disease, anatomic pulmonary resection offers the best curative potential. Traditionally, this has been achieved via posterolateral or anterolateral thoracotomy. While these approaches provide excellent exposure, they are associated with significant postoperative pain, prolonged recovery, and morbidity (2,3). Accumulated evidence demonstrates that minimally invasive thoracic surgery (MITS) confers significant benefits without compromising oncological efficacy and current clinical guidelines now strongly recommend minimally invasive approaches when technically feasible. We present this article in accordance with the Narrative Review reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1608/rc). Methods A structured literature search was conducted in PubMed, Cochrane Library, and Wiley Library for studies published through early 2026, following a narrative review methodology. Representative search terms included combinations of ‘NSCLC’, ‘lobectomy’, ‘VATS’, ‘robotic thoracic surgery’, ‘Robotic-assisted thoracic surgery’, ‘outcomes’, ‘cost-effectiveness’, and ‘minimally invasive thoracic surgery’. Studies were prioritized according to a hierarchy of evidence: randomized controlled trials (RCTs) and large-scale registry analyses were given the highest priority, followed by meta-analyses, propensity-matched observational studies, and clinical practice guidelines. Additional relevant publications were identified through manual review of reference lists from included studies. The ‘date of search’ refers to the calendar period during which database searches were executed (November 2025 through May 2026), while ‘timeframe’ refers to the calendar period during which the manuscript was drafted and revised (February to July 2026). As this is a narrative review, a formal systematic search protocol with predefined inclusion/exclusion algorithms was not employed; rather, a structured approach was used to ensure comprehensive coverage of the relevant literature (Table 1). Table 1The search strategy summaryItemsSpecificationDate of searchNovember 2025 through May 2026Databases searchedPubMed, Cochrane Library, Wiley LibrarySearch terms usedNSCLC, lobectomy, VATS, robotic thoracic surgery, outcomes, cost effectiveness, minimally invasive thoracic surgeryTimeframeFebruary to July 2026Inclusion and exclusion criteriaInclusion criteria: English language, peer-reviewed, RCTs, meta-analyses, large registry studiesExclusion criteria: non-peer-reviewed articles, animal cadaveric ex vivo or purely preclinical/stimulation studies, case reports, or case series with fewer than 10 patientsSelection processTwo authors independently screened titles/abstractsAdditional considerationsNo restrictions regarding co-morbidities or prior treatments were appliedRCT, randomized controlled trial. The search strategy summary RCT, randomized controlled trial. Evolution of MITS The posterolateral thoracotomy historically served as the gold standard for anatomic lung resection. This approach, however, carries substantial morbidity—requiring extensive soft tissue dissection, rib spreading, and serratus anterior or latissimus dorsi division—frequently resulting in significant pain and prolonged recovery. MITS has emerged as a paradigm shift, encompassing surgical approaches that substantially reduce chest wall trauma while preserving oncological and functional equivalence (4,5). MITS includes video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracic surgery (RVATS) and their variations: multiport, uniport, hybrid, and hand-assisted techniques. VATS, first introduced in the early 1990s, fundamentally transformed the modern approach to thoracic procedures (6). Critical to this advancement was the concurrent development of the endoscopic linear stapler—adapted from gastrointestinal stapling devices for percutaneous use—which for the first time enabled the safe division of bronchi, vessels, and lung parenchyma through small port incisions (7). By replacing the traditional thoracotomy with two to three small port incisions and an accessory incision, VATS enabled anatomic lung resection under video guidance with the goal of reducing chest wall trauma while maintaining oncological principals (8). Early adoption was tempered by concerns regarding oncological adequacy, technical feasibility for complex hilar dissection, and the quality of mediastinal lymph node assessment. Over the ensuing decade, accumulating evidence has validated the safety and oncological equivalence of VATS lobectomy (9). The subsequent development of uniportal VATS pushed this innovation further. By consolidating access to a single incision, uniportal VATS has demonstrated reduced postoperative pain, shorter operative times, and shorter chest tube drainage when compared with multiportal VATS (10). While this review focuses on lobectomy, anatomical segmentectomy has emerged as a standard option for peripheral NSCLC ≤2 cm following the JCOG0802/WJOG4607L and CALGB 140503 phase III trials which demonstrated non-inferiority of segmentectomy—and in JCOG0802, superior overall survival (OS)—compared with lobectomy (11,12). Minimally invasive approaches to segmentectomy have followed a similar trajectory: Society of Thoracic Surgeons (STS) Database demonstrates that both VATS and robotic segmentectomy achieve comparable rates of lymph node upstaging and are associated with fewer postoperative complications and shorter hospital stays compared with open segmentectomy (12). A meta-analysis of propensity-matched studies found comparable perioperative safety, oncological adequacy, and survival between RVATS and VATS segmentectomy (13). The robotic platform may facilitate more complex segmental resections through enhanced visualization of intersegmental planes and segmental broncho-vascular anatomy, though definitive evidence of clinical superiority over VATS remains limited. Despite these advances, VATS carries inherent technical limitations. Rigid, straight instruments produce a fulcrum effect at the incision site, two-dimensional imaging eliminates depth perception, and counterintuitive hand-eye coordination constrain the surgeon’s ability to perform complex maneuvers in a confined space—particularly during a difficult hilar dissection or advanced lymphadenectomy (8,14). The robotic platform, introduced in the early 2000s, was designed to overcome the limitations inherent to VATS while preserving the benefits of a minimally invasive approach (14). Key advantages include enhanced ergonomics, three-dimensional high-definition visualization restoring depth-perception, and articulated wristed instruments that replicate and surpass the degrees of freedom of the human hand (8). These features have expanded the scope of minimally invasive surgery to include more complex procedures that may have been prohibitive via conventional VATS (9,15). Collectively, these technological milestones have helped shift the balance toward reducing surgical trauma without compromising the quality of anatomical dissection. Adoption of the robotic approach has accelerated rapidly. In the USA, robotic lobectomy (RL) had grown to account for nearly 25% of lobectomy volume by 2014 and now accounts for nearly half of all minimally invasive lung resections in the USA (15-17). The transition from open thoracotomy to MITS represents a continuum of innovation. Single-port (SP) robotic platforms represent the latest frontier, combining the reduced access trauma of uniportal surgery with the superior dexterity and visualization afforded by robotic instrumentation (18,19). Iatrogenic injuries Intraoperative complications during MITS represent a critical safety concern and are a major driver of unplanned conversion to thoracotomy. Conversion itself carries significant consequences. A systematic review and meta-analysis of over 72,000 VATS anatomic lung resections estimated a median conversion rate of 9.6%, with conversion associated with more than a twofold increase in postoperative complications [odds ratio (OR) 4.11, 95% confidence interval (CI): 1.59–10.61] (20). Understanding the nature and frequency of intraoperative injuries is therefore essential for risk mitigation and surgical planning. Vascular injury during VATS Vascular injury is consistently the most common major intraoperative complication during VATS anatomic lung resection. In a multicenter European analysis of 3,706 VATS anatomical lung resections, vascular injuries occurred in 2.9% of patients and led to conversion in 2.2% (21). Other major intraoperative complications were identified in 1.5% of cases and included erroneous transection of bronchoalveolar structures, injuries to gastrointestinal structures, and proximal airway injury (21). Critically, 23% of in-hospital mortalities were attributable to these major intraoperative complications, and eight pneumonectomies were performed as a consequence of intraoperative injury (21). These findings have been corroborated across other large registries. In the Italian VATS Group registry of over 4,000 VATS lobectomies, the overall conversion rate was 9.2% with vascular injuries leading to conversion in 2.6% of patients (22). This study also demonstrated that conversion rates were significantly higher at low-volume centers, though the relationship between surgical experience and vascular injury specifically was less clear (22). A case-control study consisting of 1,064 VATS anatomical pulmonary resections identified the pulmonary artery as the most frequently injured vessel, with thermal injury as the predominant mechanism (23). Intraoperative complications during robotic surgery Among robotic cases, a video-based analysis of 215 robotic segmentectomies identified intraoperative complications in 8.8% of cases with injuries to the pulmonary artery (4.2%), bronchi (1.9%), pulmonary vein (0.9%), and pleura (1.9%) (24). Notably, all complications in this series were managed without blood transfusion or conversion to thoracotomy, underscoring the potential for intracorporeal rescue with the robotic platform (24). In a separate single-institution series of 134 robotic anatomical pulmonary resections, intraoperative complications occurred in 12.7% of patients, again predominately involving the pulmonary artery; no cases required conversion to thoracotomy (25). Conversion patterns Importantly, the pattern of conversion differs between platforms. Data from the STS General Thoracic Surgery Database encompassing 27,695 minimally invasive lobectomies demonstrated that overall conversion rates are lower with robotic approach compared with VATS (6.0% vs. 11.0%, P<0.001) (26). However, when conversion does occur during robotic surgery, it is more frequently emergent (P<0.001) and more often precipitated by vascular injury (P<0.001) compared with VATS, where anatomical difficulty and adhesions are more common drivers of conversion (26). Despite these differences in conversion etiology, overall complication rates and mortality following conversion were comparable between the two approaches (26). The role of haptic feedback The absence of haptic feedback in current robotic platforms is a recognized contributor to iatrogenic injury. Without tactile sensation, the surgeon cannot perceive tissue tension or resistance during dissection, potentially leading to excessive force application and inadvertent vascular or parenchymal injury (24). A meta-analysis of 56 studies comparing robotic surgery with and without haptic feedback demonstrated that restoring tactile sensation significantly reduced applied forces (Hedges’ g=0.83), peak forces (Hedges’ g=0.69), and improved task accuracy (Hedges’ g=1.50) (27). These findings suggest that the incorporation of haptic feedback into future robotic platforms may meaningfully reduce the incidence of iatrogenic injury during thoracic procedures. Morbidity A reduction in postoperative complications is one of the most compelling surgical advantages of a MITS approach. In a propensity-matched cohort study of 2,562 patients from the STS General Thoracic Database, VATS lobectomy was associated with significantly fewer overall complications compared with open lobectomy (OL) (26% vs. 35%, P<0.001) (28). This advantage extended across specific complication categories, including fewer pulmonary complications (8% vs. 12%; P<0.001), less atrial fibrillation requiring treatment (7% vs. 12%; P<0.001), and fewer blood transfusions (2% vs. 5%; P=0.003) (28). These findings were corroborated by the European Society of Thoracic Surgeons (ESTS) database, in which a propensity-matched analysis of 5,442 patients confirmed lower overall complication rates (29.1% vs. 31.7%, P=0.04), lower major cardiopulmonary complications, and reduced in-hospital mortality (1.0% vs. 1.9%; P=0.02) (29). Notably, the VIOLET trial—the largest multicenter RCT comparing VATS with OL—provided the highest level of evidence confirming these observational findings (30). The proportion of patients experiencing in-hospital adverse events was significantly lower in the VATS group [33% vs. 44%; relative risk (RR) 0.74; 95% CI: 0.66–0.84; P<0.001] (30). The most comprehensive three-way comparison comes from data collected in the PORTaL study in which both RL and VATS demonstrated significantly fewer overall postoperative complications compared with OL while complication rates between RL and VATS were comparable (31). Taken together, these data indicate that the primary clinical advantage of MITS is relative to open thoracotomy, while outcomes between RVATS and VATS remain largely comparable across most perioperative domains. Estimated blood loss (EBL) Intraoperative blood loss directly impacts transfusion requirements, hemodynamic stability, and postoperative recovery. Both VATS and RVATS consistently demonstrate significantly lower EBL compared with open thoracotomy for lobectomy. In an RCT of 425 patients, Long et al. demonstrated that VATS lobectomy was associated with significantly less intraoperative blood than axillary thoracotomy (P<0.001) (32). Similarly, Bendixen et al. reported in a separate RCT that median perioperative blood loss was 50 mL [interquartile range (IQR) 25–100 mL] after VATS compared with 100 mL (IQR 50–200 mL) after anterolateral thoracotomy (P=0.04) (2). A meta-analysis by encompassing nine studies confirmed significantly less intraoperative blood loss with VATS, including in the post-induction therapy setting (P=0.04) (33). While both minimally invasive approaches demonstrate lower EBL than open surgery, RVATS often demonstrates a marginal statistical advantage over VATS. A meta-analysis of prospective studies encompassing 614 patients found significantly less blood loss in the RVATS group [mean difference (MD) =−17.14 mL, 95% CI: −29.96 to −4.33; P=0.009] (34). A larger meta-analysis consisting of 45,733 patients across 26 studies corroborated this finding, reporting less blood loss with RVATS alongside a lower conversion rate and shorter hospital stay (35). Blood transfusions Postoperative blood transfusion rates across all three modalities remain relatively low in the elective setting, though a consistent gradient favoring minimally invasive approaches is evident. In an STS Database propensity-matched analysis of 2,562 patients, VATS lobectomy was associated with significantly fewer blood transfusions than open thoracotomy (2.4% vs. 4.7%, P=0.003) (36). The multicenter PORTAL study consisting of 5,721 cases across 21 institutions confirmed lower transfusion rates for both RL and VATS compared to OL, and further demonstrated a significantly lower postoperative transfusion rate for RL compared with VATS (P=0.01) (31). Overall, the cumulative effect of reduced chest wall trauma and more precise vascular dissection with minimally invasive techniques—particularly the robotic platform—translates into a measurable reduction in transfusion burden. Notably, while these statistical differences are reproducible, the absolute magnitude of the blood loss reduction between RVATS and VATS is modest and of uncertain clinical significance. Chest tube duration Chest tube duration plays an important role in postoperative recovery, patient comfort, and discharge readiness. Data from the STS General Thoracic Database demonstrated that VATS lobectomy was associated with earlier chest tube removal when compared to open thoracotomy (median 3 days vs. 4 days; P<0.001) (28). When comparing the two minimally invasive platforms, several studies report shorter chest tube duration with RVATS. In a propensity-matched analysis of NSCLC patients after neoadjuvant therapy, a median chest tube duration of 4 days (IQR 3–5 days) following RVATS was demonstrated compared with 5 days (IQR 3–6 days) for VATS (P=0.002) (37). This finding, however, is not consistent across all studies: a meta-analysis of 45,733 patients across 26 studies found no significant difference in chest drain duration between RVATS and VATS (35). These discrepancies could reflect variability in institutional chest tube management and patient selection. Pain Studies demonstrate a significant reduction in postoperative pain with MITS compared with open thoracotomy, with minimal difference in postoperative pain between VATS and RVATS. In an RCT of 206 patients with stage I NSCLC, VATS was associated with significantly lower postoperative pain and superior self-reported quality of life throughout the first year compared to anterolateral thoracotomy (2). Clinically relevant pain [numerical rating scale (NRS) ≥3] within the first 24 hours was reported by 38% of VATS patients versus 63% in the open group, with shorter median epidural duration (2 vs. 3 days) (2). Similar benefits have been observed with RVATS, with one comparative study reporting lower pain levels at rest from postoperative day (POD) 1 through 8 (38). Minimally invasive techniques also significantly reduce opioid consumption compared with open approaches, with studies reporting 27–35% lower median daily morphine milligram equivalents (MME) after MITS (39,40). Differences between RVATS and VATS are less pronounced and data remain mixed: some studies report modestly lower opioid use with RVATS, while others show no significant difference or even higher consumption post-RVATS (39,41,42). Length of hospital stay (LOS) One of the most consistently demonstrated advantages of MITS is a reduced LOS when compared with open thoracotomy. Data from the STS General Thoracic Database demonstrated that VATS lobectomy was associated with a median LOS of 4 days compared with 6 days for thoracotomy (P<0.001) (28). Data in the VIOLET trial confirmed a shorter median LOS in the VATS group compared with OL (4 vs. 5 days, P=0.006) (30). The PORTaL study provided the most comprehensive comparative data across all three approaches. Both RVATS and VATS demonstrated a significantly shorter LOS compared with OL (P<0.02), and RL was associated with an even shorter LOS than VATS (31). This stepwise reduction has been replicated in other datasets: a propensity-matched analysis, the median LOS was 4 days for RL, 5 days for VATS, and 6 days for OL (P=0.001) (43). Lower conversion rates and reduced tissue trauma may contribute to accelerated postoperative mobilization and optimized hospital resource utilization. Recovery Beyond the immediate clinical advantages observed during hospitalization, the benefits of MITS extend to the long-term recovery phase. The VIOLET trial reported that VATS patients demonstrated significantly better physical function and global health status by week five, required less physiotherapy, and reached earlier mobilization compared with OL (43). Long-term data in older adults (≥70 years) further support these benefits, with data demonstrating that VATS was independently associated with a higher probability of “time-at-home” and reduced homecare needs over five years compared with open surgery (44). Despite these demonstrated advantages, functional recovery is not immediate. A study within an established enhanced recovery after surgery (ERAS) programme found that patient physical activity remained significantly below preoperative baseline at 7 days post-discharge (P<0.001), with fatigue and pain as the dominant barriers to recovery (45). Mortality A critical question in the evaluation of any operative approach is perioperative mortality. Both minimally invasive platforms—VATS and RVATS—demonstrate a significant survival advantage over open thoracotomy for early-stage lung cancer resection. In a systematic review of 61,633 patients across 33 studies, VATS demonstrated lower postoperative mortality (OR 0.64; 95% CI 0.56–0.73) and higher long-term survival [hazard ratio (HR) 0.88; 95% CI: 0.81–0.96] compared with OL (45). In a recent individual patient data (IPD) meta-analysis of 1,185 patients from 3 RCTs, VATS conferred a 21% reduction in the risk of death compared with open surgery (pooled HR 0.79; 95% CI: 0.65–0.96) (46). While direct comparisons between VATS and RVATS suggest broadly similar mortality, some data favor the robotic approach. A meta-analysis by Wu et al. of 50,404 patients across 25 studies found significantly lower 30-day mortality with RVATS compared with VATS (47,48). However, the highest quality comparative data, including the PORTaL study and an analysis of the STS database, report comparable in-hospital and 30-day mortality between the two MITS approaches (31,49). It should be noted that mortality comparisons between RVATS and VATS derived exclusively from observational studies and meta-analyses thereof; no RCT has yet directly compared mortality between these two approaches. Oncological outcomes Nodal upstaging Accurate intraoperative lymph node staging is critical, as detection of occult nodal disease influences adjuvant therapy decisions and prognosis. Early data from the National Cancer Database (NCDB) suggests that an open approach yields higher nodal upstaging (12.6%) compared to VATS (11.7%) and RVATS (11.2%), although VATS—not RVATS—was associated with lower rates of harvesting ≥10 lymph nodes and sampling ≥5 nodal stations compared with open approach (50). More recent data, however, have challenged the clinical significance of this difference. A supplementary analysis however of the JCOG 1413 phase 3 trial, which included 1,685 patients with clinical stage I–II NSCLC, found no significant difference in N2 upstaging between VATS and open thoracotomy after propensity score matching (7.8% vs. 7.3%; P=0.80), with equivalent median N2 node counts (51). The 2026 IPD meta-analysis of three RCTs similarly reported negligible differences in nodal upstaging between VATS and open surgery, cN0 to pN1 of 7% and cN0 to pN2 of 8% in both approaches, challenging the hypothesis that open surgery provided superior staging (46). The 2025 American College of Chest Physicians (ACCP) guidelines concluded there was oncologic equivalence between MITS and thoracotomy for nodal upstaging and OS, issuing a strong recommendation for a minimally invasive approach over thoracotomy in clinical stage I NSCLC (17). Comparative assessment including the robotic approach yields similar findings. An NCDB analysis of 24,257 patients with clinical T2–3N0 disease demonstrated no significant difference in N1 upstaging (robotic 11.79%, VATS 11.49%, open 11.85%; P=0.27) or N2 upstaging (5.03%, 5.66%, 6.15%; P=0.27) between the three approaches (52). In a propensity-score adjusted analysis, RL was associated with similar overall nodal upstaging to OL (16.2% vs. 21.8%), while VATS had significantly lower upstaging (12.3%) (53). It is important to note that the strongest evidence for oncological equivalence between MITS and open thoracotomy derives from RCTs and their pooled analyses, whereas comparison between RVATS and VATS in this domain rely predominantly on retrospective registry and observational data. Although some studies suggest modestly higher overall upstaging with open surgery, and potentially more thorough lymphadenectomy with RVATS versus VATS, guideline consensus and highest-quality evidence indicate that all three approaches provide adequate nodal staging when performed by experienced surgeons adhering to oncological principles. Margins & completeness of resection A fundamental oncological requirement in lung cancer is achieving a negative (R0) resection margin. Current data demonstrate comparable R0 resection rates across all three surgical approaches. A meta-analysis of 183,426 patients across 34 studies identified no significant difference in positive resection margins among open, VATS, or RVATS lobectomy (54). Notably, one large analysis reported a higher rate of positive margins among an open approach with no difference reported between VATS and RVATS (55). It is critical however to consider the role of selection bias in these findings as open thoracotomy is disproportionately utilized in more complex or larger T-stage tumors. The lack of significant difference in R0 resection rates among RVATS and VATS has been consistent with no data supporting one approach superior. Disease-free survival (DFS) DFS, defined as the time from surgery to disease recurrence or death from any cause, more directly measures the effectiveness of the surgical approach at preventing cancer recurrence than OS. The totality of evidence indicates that DFS is similar across all three surgical approaches when performed by experienced surgeons adhering to oncological principals. The 2026 IPD meta-analysis by Harris et al. demonstrated a 21% reduction in mortality risk for VATS over OL (pooled HR 0.79), but DFS showed only a non-significant 9% reduction (pooled HR 0.91) (46). A post-hoc analysis restricted to the first two years did reveal a statistically significant DFS advantage favoring VATS, which the author contributed to reduced perioperative morbidity rather than superior cancer control—early non-cancer deaths from surgical complications disproportionately contribute to DFS events in this window, explaining the divergence that attenuates over time (46). This survival advantage is attributed to reduced perioperative mortality rather than cancer-specific outcomes, as DFS was similar between the two groups (46). Comparative data between the MITS platforms remains largely equivocal and the current evidence does not demonstrate a clinically meaningful oncological advantage of one minimally invasive platform over the other (56,57). The RVlob RCT (320 patients, median follow-up 58 months) demonstrated non-inferior 3-year OS for RL compared with VATS (94.6% vs. 91.5%; P=0.003) with similar 3-year DFS (88.7% vs. 85.4%; P=0.62) (57). Equivalent outcomes were also confirmed with data obtained in another meta-analysis of 2,045 patients across 10 studies that demonstrated similar OS and DFS between RVATS and VATS (56). Cost analysis At the procedural level, open thoracotomy demonstrates the lowest operating room (OR) costs ($8,698 vs. $9,491 for VATs vs. $9,912 for robotic, P=0.001) (58). Decreased operative times and the absence of specialized instrumentation contribute to the decreased procedural cost observed with the open approach. Higher intraoperative costs of minimally invasive approaches are offset by reduced postoperative resource utilization. Both VATS and RVATS are associated with significantly shorter LOS and fewer postoperative complications resulting in decreased total hospital cost, although not statistically significant ($17,223 robotic vs. $17,260 VATS vs. $18,075, P=0.48) (58). Patient-level data consistently shows VATS as the least expensive option with RL 13% more expensive with a notable $17,860 in excess patient charges in one study ($90,593 vs. $72,733, P=0.001) (59). This cost gap is narrowed at high-volume centers. The RAVAL randomized trial demonstrated an incremental cost-effectiveness ratio of $14,926 per quality-adjusted life year (QALY) for RL, suggesting cost-effectiveness may improve with increased surgeon experience (60). Beyond perioperative costs, the overall economic evaluation of robotic surgery must account for substantial capital and fixed costs. The da Vinci robotic system carries an acquisition cost estimated at $1.0–2.5 million, with annual maintenance contracts of approximately $80,000–170,000 (61,62). Additionally, robotic instruments carry manufacturer-imposed usage limits (typically ≤10 procedures per instrument), contributing an estimated $1,866 per procedure in instrument and accessory cost alone—substantially higher than conventional endoscopic instrumentation (61). Institutional surgical volume is a critical determinant of cost-effectiveness, as higher case volumes allow amortization of fixed costs across more procedures. An activity-based cost analysis demonstrated that when robotic programs achieve sufficient volume, overall controllable costs may actually favor the robotic approach due to reduced length of stay and postoperative resource utilization ($16,352 robotic vs. $21,154 VATS, P=0.03) (63). These findings underscore the cost-effectiveness of robotic thoracic surgery is not solely determined by procedural costs but is heavily influenced by institutional volume, case selection, and the ability to leverage reduced postoperative resource utilization to offset higher upfront investment. Future directions The evolution of MITS presents a significant training challenge. Cumulative sum analyses indicate that the robotic learning curve (RLC) requires 20 to 40 cases for initial proficiency and over 60 for mastery with continued improvements in efficiency observed beyond 100 cases for lobectomy (64-67). Prior VATS experience does not appear to meaningfully shorten this trajectory. Proficiency for operative time targets was similarly challenging across de-novo, open-to-robotic, and VATS-to-robotic transition groups in an STS Database analysis of 5,619 RLs (67). Encouragingly, patients treated by surgeons during the RLC may experience better outcomes than patients who were treated during the VATS learning curve with shorter chest tube duration and LOS (68). The trajectory of robotic thoracic surgery is increasingly oriented toward port reduction. Emerging biportal or dual-port robotic approaches represent an intermediate strategy between conventional RVATS and SP platforms, early multi-institutional experience with dual-port RVATS for anatomical lung resection has demonstrated feasibility and safety, with no conversions to thoracotomy, minimal blood loss (mean 9.6 g), and low postoperative pain scores (69). Similarly, a two-port versus three-port lobectomy comparison demonstrated shorter operative times (P=0.01) and reduced early postoperative pain (P<0.01) with the two-port approach without compromising lymph node yield or safety (70). These reduced-port robotic techniques may serve as a practical transitional step for surgeons adopting SP robotic platforms and warrant further investigation in larger comparative studies. SP robotic platforms represent the current frontier, aiming to combine the minimal access of uniportal VATS with the multidimensional dexterity of robotic instrumentation. A prospective multicenter feasibility study of the da Vinci SP (Intuitive Surgical, Inc., Sunnyvale, CA, USA) system demonstrated successful completion of 19 lobectomies through a subcostal uniportal approach without conversion, achieving a 100% R0 resection rate with a median of 6.5 nodal stations sampled and 17.5 nodes resected per patient (71). It should be noted that evidence for biportal/dual-port and SP robotic platforms currently derive from early feasibility studies and small comparative series; prospective multicenter trials are needed to establish their role relative to established multiport techniques. Finally, the integration of artificial intelligence (AI) into thoracic surgery is anticipated to further reduce iatrogenic injury and flatten the learning curve for complex procedures. AI-driven technologies which include computer vision, augmented reality, and automated three-dimensional (3D) broncho-vascular reconstruction have already demonstrated improved identification of segmental anatomy, reduced operative times, and are anticipated to further enhance intraoperative safety and expand the scope of MITS (72,73). Limitations This narrative review has several limitations. The literature search was not exhaustive, and study selection was subject to potential bias. The majority of comparative data derive from retrospective observational studies and registry analyses, which are susceptible to selection bias—surgeons may reserve open thoracotomy for more complex cases, confounding direct comparisons. Propensity-score matching partially mitigates this, but residual confounding cannot be excluded. RCT data comparing all three approaches remain limited; no RCT has compared RVATS with open thoracotomy, and only one (RVlob) has compared RVATS with VATS (57). Heterogeneity in technique definitions (e.g., multiport vs. uniport VATS, three- vs. four-arm robotic approaches), institutional protocols, and variable outcome reporting further limit the generalizability of pooled comparisons. Finally, cost analyses are predominantly based on USA healthcare data and may not be applicable to other systems Conclusions Evidence supporting MITS as the modern standard for anatomic pulmonary resection is robust and continues to strengthen. Compared with open thoracotomy, both VATS and RVATS consistently demonstrate reduced perioperative mortality, fewer postoperative complications, less pain, shorter hospitalizations, and faster functional recovery—all without compromising oncological outcomes including nodal staging, margin status, and DFS. While the choice between VATS and RVATS often depends on institutional resources, surgical volume, and surgeon experience, emerging data suggests that the robotic platform may offer technical advantages in ergonomics, visualization, and complex hilar dissection, though these have not yet consistently translated into superior clinical outcomes compared with VATS. Large multicenter RCTs directly comparing RVATS and VATS across diverse clinical settings are needed to further define the relative benefits of each minimally invasive approach. As SP robotic systems and AI-driven technologies mature, the frontier of MITS will continue to evolve and further minimize surgical trauma while maximizing precision and oncological integrity. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Provenance and Peer Review: This article was commissioned by the Guest Editors (Roman V. Petrov and Andrei I. Gritsiuta) for the series “Complications in Anatomical Lung Resection: A Comprehensive Surgical Perspective” published in Journal of Thoracic Disease. The article has undergone external peer review. Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1608/rc Funding: None. Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1608/coif). The series “Complications in Anatomical Lung Resection: A Comprehensive Surgical Perspective” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare. References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1608/prf Supplementary Materials The article’s supplementary files as